REFERENCES
1. López-Pascual E, Rienda I, Perez-Rojas J, et al. Drug-induced fatty liver disease (DIFLD): a comprehensive analysis of clinical, biochemical, and histopathological data for mechanisms identification and consistency with current adverse outcome pathways. Int J Mol Sci. 2024;25:5203.
2. Kleiner DE, Chalasani NP, Lee WM, et al; Drug-Induced Liver Injury Network (DILIN). Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology. 2014;59:661-70.
3. Ipsen DH, Lykkesfeldt J, Tveden-Nyborg P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell Mol Life Sci. 2018;75:3313-27.
4. Begriche K, Massart J, Robin MA, Bonnet F, Fromenty B. Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease. Hepatology. 2013;58:1497-507.
5. Chalasani N, Younossi Z, Lavine JE, et al; American Gastroenterological Association, American Association for the Study of Liver Diseases, American College of Gastroenterologyh. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142:1592-609.
6. Kolaric TO, Nincevic V, Kuna L, et al. Drug-induced fatty liver disease: pathogenesis and treatment. J Clin Transl Hepatol. 2021;9:731-7.
7. Hosack T, Damry D, Biswas S. Drug-induced liver injury: a comprehensive review. Therap Adv Gastroenterol. 2023;16:17562848231163410.
9. Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJ. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov. 2010;9:325-38.
10. Pfefferlé M, Dubach IL, Buzzi RM, et al. Antibody-induced erythrophagocyte reprogramming of Kupffer cells prevents anti-CD40 cancer immunotherapy-associated liver toxicity. J Immunother Cancer. 2023;11:e005718.
11. Bath RK, Brar NK, Forouhar FA, Wu GY. A review of methotrexate-associated hepatotoxicity. J Dig Dis. 2014;15:517-24.
12. Di Pasqua LG, Cagna M, Berardo C, Vairetti M, Ferrigno A. Detailed molecular mechanisms involved in drug-induced non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: an update. Biomedicines. 2022;10:194.
13. Todorović Vukotić N, Đorđević J, Pejić S, Đorđević N, Pajović SB. Antidepressants- and antipsychotics-induced hepatotoxicity. Arch Toxicol. 2021;95:767-89.
14. Slim M, Medina-Caliz I, Gonzalez-Jimenez A, et al. Hepatic safety of atypical antipsychotics: current evidence and future directions. Drug Saf. 2016;39:925-43.
15. Carli M, Kolachalam S, Longoni B, et al. Atypical antipsychotics and metabolic syndrome: from molecular mechanisms to clinical differences. Pharmaceuticals. 2021;14:238.
16. Leise MD, Poterucha JJ, Talwalkar JA. Drug-induced liver injury. Mayo Clin Proc. 2014;89:95-106.
17. Anand K, Ensor J, Trachtenberg B, Bernicker EH. Osimertinib-induced cardiotoxicity: a retrospective review of the FDA Adverse Events Reporting System (FAERS). JACC CardioOncol. 2019;1:172-8.
18. Kamimura H, Setsu T, Kimura N, et al. Analysis of drug-induced liver-related adverse event trend reporting between 1997 and 2019. Hepatol Res. 2023;53:556-68.
19. Yang Z, Lv Y, Yu M, et al. GLP-1 receptor agonist-associated tumor adverse events: a real-world study from 2004 to 2021 based on FAERS. Front Pharmacol. 2022;13:925377.
20. Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999;20:109-17.
21. Shu Y, He X, Liu Y, Wu P, Zhang Q. A real-world disproportionality analysis of Olaparib: data mining of the public version of FDA Adverse Event Reporting System. Clin Epidemiol. 2022;14:789-802.
22. Wang Y, Zhao B, Yang H, Wan Z. A real-world pharmacovigilance study of FDA adverse event reporting system events for sildenafil. Andrology. 2024;12:785-92.
23. Cui Z, Cheng F, Wang L, et al. A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say? Front Pharmacol. 2023;14:1259908.
24. Posner J, Barrington P, Brier T, Datta-Mannan A. Monoclonal antibodies: past, present and future. In: Barrett JE, Page CP, Michel MC, editors. Concepts and principles of pharmacology. Cham: Springer International Publishing; 2019. pp. 81-141.
25. Boyiadzis M, Foon KA. Approved monoclonal antibodies for cancer therapy. Expert Opin Biol Ther. 2008;8:1151-8.
26. Perosa F, Luccarelli G, Prete M, Dammacco F. Monoclonal antibodies in the immunotherapy of autoimmune diseases. Ann Ital Med Int. 2001;16:220-32.
27. Chun LJ, Tong MJ, Busuttil RW, Hiatt JR. Acetaminophen hepatotoxicity and acute liver failure. J Clin Gastroenterol. 2009;43:342-9.
28. De Martin E, Michot JM, Rosmorduc O, Guettier C, Samuel D. Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors. JHEP Rep. 2020;2:100170.
29. Chen J, Deng X, Liu Y, et al. Kupffer cells in non-alcoholic fatty liver disease: friend or foe? Int J Biol Sci. 2020;16:2367-78.
30. Schmidt S, Messner CJ, Gaiser C, Hämmerli C, Suter-Dick L. Methotrexate-induced liver injury is associated with oxidative stress, impaired mitochondrial respiration, and endoplasmic reticulum stress in vitro. Int J Mol Sci. 2022;23:15116.
31. Di Martino V, Verhoeven DW, Verhoeven F, et al. Busting the myth of methotrexate chronic hepatotoxicity. Nat Rev Rheumatol. 2023;19:96-110.
32. French JB, Bonacini M, Ghabril M, Foureau D, Bonkovsky HL. Hepatotoxicity associated with the use of anti-TNF-α agents. Drug Saf. 2016;39:199-208.
33. Ramadori G, Cameron S. Effects of systemic chemotherapy on the liver. Ann Hepatol. 2010;9:133-43.
35. Tolman KG, Chandramouli J. Hepatotoxicity of the thiazolidinediones. Clin Liver Dis. 2003;7:369-79, vi.
36. Khan RS, Bril F, Cusi K, Newsome PN. Modulation of insulin resistance in nonalcoholic fatty liver disease. Hepatology. 2019;70:711-24.
37. Wu L, Li Z, Gao N, et al. Interferon-α could induce liver steatosis to promote HBsAg loss by increasing triglyceride level. Heliyon. 2024;10:e32730.
38. Sørensen P, Edal AL, Madsen EL, Fenger C, Poulsen MR, Petersen OF. Reversible hepatic steatosis in patients treated with interferon alfa-2A and 5-fluorouracil. Cancer. 1995;75:2592-6.
39. Choudhari P, Patni N. Updates in the management of pediatric dyslipidemia. Curr Opin Lipidol. 2023;34:156-61.
40. Kumar N, Kalaiselvan V, Arora MK. Neuronal toxicity of monoclonal antibodies (mAbs): an analysis of post-marketing reports from FDA Adverse Event Reporting System (FAERS) safety database. Eur J Clin Pharmacol. 2024;80:1685-95.
41. Kaplowitz N, Aw TY, Simon FR, Stolz A. Drug-induced hepatotoxicity. Ann Intern Med. 1986;104:826-39.
42. Kral JG, Schaffner F, Pierson RN Jr, Wang J. Body fat topography as an independent predictor of fatty liver. Metabolism. 1993;42:548-51.
44. Tran K, McCormack S. Exercise for the treatment of ankle sprain: a review of clinical effectiveness and guidelines. 2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK563007/. [Last accessed on 24 Oct 2025].
45. Niederberger E, Kuner R, Geißlinger G. Pharmacological aspects of pain research in Germany. Schmerz. 2015;29:531-8. (in German).
46. Te H, Doucette K. Viral hepatitis: guidelines by the American Society of Transplantation Infectious Disease Community of Practice. Clin Transplant. 2019;33:e13514.
